【摘要】 目的 评价一次性使用血液灌流器(UA230)通过血浆灌流技术治疗难治性痛风(Refractory Gout, RG)的有效性及安全性。方法 招募18～65岁的难治性痛风患者34例，按照治疗方法不同随机分为对照组(非布司他治疗，17例)与试验组(血浆灌流+非布司他治疗，17例),采用χ~2/t检验分析两组患者尿酸水平、尿酸下降率、不良反应发生率有无差异。结果 治疗后7 d、14 d试验组尿酸水平低于对照组，尿酸下降率高于对照组，差异有统计学意义(P均<0.05),而治疗后28d两组患者尿酸水平、尿酸下降率差异无统计学意义(P均>0.05);两组患者不良反应发生率对比无统计学差异(χ~2=0.15,P>0.05)。结论 应用一次性使用血液灌流器(UA230)通过血浆灌流技术治疗RG是安全有效的，未来有望成为RG患者的全新治疗方法。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of the single-use hemoperfusion device(UA230)in treating refractory gout(RG) via plasma perfusion. Methods Thirty-four RG patients aged 18-65 years were recruited and randomly divided into a control group(febuxostat therapy, n=17) and an experimental group(plasma perfusion combined with febuxostat therapy, n=17). Differences in serum uric acid(SUA) levels and urate-lowering rates between the two groups were analyzed using t-tests. Between-group differences in incidence of adverse reactions were analyzed using chi-square tests. Results At 7 and 14 days post-treatment, SUA levels in the experimental group were significantly lower than those in the control group, with a higher urate-lowering rate(all P<0.05). However, no statistically significant differences in SUA levels or urate-lowering rate were observed at 28 days post-treatment(all P>0.05). The incidence of adverse reactions showed no significant difference between the two groups(χ~2=0.15, P>0.05). Conclusion The single-use hemoperfusion device(UA230), combined with plasma perfusion technology, is a safe and effective treatment for RG. It may serve as a novel therapeutic approach for RG patients in clinical practice.更多还原